ProPhase Labs (PRPH) Receives Media Impact Rating of 0.22

News articles about ProPhase Labs (NASDAQ:PRPH) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ProPhase Labs earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.6132514235165 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of PRPH stock remained flat at $$2.88 on Tuesday. 154 shares of the company traded hands, compared to its average volume of 13,197. ProPhase Labs has a fifty-two week low of $1.84 and a fifty-two week high of $3.43. The firm has a market capitalization of $33.06 and a P/E ratio of 3.86.

WARNING: This piece of content was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://weekherald.com/2018/04/24/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-prophase-labs-prph-share-price.html.

About ProPhase Labs

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.

Insider Buying and Selling by Quarter for ProPhase Labs (NASDAQ:PRPH)

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply